Literature DB >> 12479939

Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma.

Takahiro Uenishi1, Shoji Kubo, Kazuhiro Hirohashi, Hiromu Tanaka, Taichi Shuto, Takatsugu Yamamoto, Akihiro Tamori, Seikan Hai, Hiroaki Kinoshita, Shuhei Nishiguchi.   

Abstract

Although interferon (IFN) therapy suppresses the development of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), the relationship between response to previous IFN therapy and postoperative outcome has not been clarified in patients who underwent curative resection for HCC. Of 175 patients who underwent curative hepatic resection for HCV-related HCC, 24 patients had HCC detected after IFN therapy. 11 patients who had a biochemical response (a normalized alanine aminotransferase (ALT) activity with or without disappearance of serum HCV RNA) were classified as the response group, while 13 patients were classified as the non-response group because they had no decrease in their ALT activity and had persistence of serum HCV RNA. The non-IFN group included 151 patients who had not received previous IFN therapy. The clinicopathologic findings and surgical outcomes were compared among these three groups. The serum activities of the aspartate aminotransferase and ALT just before surgery were significantly lower in the response group than in the other groups. Although no significant differences were noted in the other clinicopathologic findings or the operation method among these groups, the tumor-free survival rate of the response group was significantly higher than that of the two other groups. By multivariate analysis, the response group had an independently lower risk for postoperative recurrence (risk ratio, 0.07; P=0.0072). Hepatic resection offers hope for low incidence of postoperative recurrence in patients with HCC, especially when previous IFN therapy has controlled their active hepatitis associated with HCV.

Entities:  

Year:  2002        PMID: 12479939     DOI: 10.1016/s1386-6346(02)00147-x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  15 in total

1.  Interferon therapy and prevention of hepatocellular carcinoma in hepatitis C.

Authors:  Amit G Singal; Jorge A Marrero
Journal:  Dig Dis Sci       Date:  2012-02-22       Impact factor: 3.199

2.  Surgical outcomes and clinical characteristics of elderly patients undergoing curative hepatectomy for hepatocellular carcinoma.

Authors:  Fumitoshi Hirokawa; Michihiro Hayashi; Yoshiharu Miyamoto; Mitsuhiro Asakuma; Tetsunosuke Shimizu; Koji Komeda; Yoshihiro Inoue; Atsushi Takeshita; Yuro Shibayama; Kazuhisa Uchiyama
Journal:  J Gastrointest Surg       Date:  2013-09-04       Impact factor: 3.452

3.  Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy.

Authors:  Shoji Kubo
Journal:  Clin J Gastroenterol       Date:  2009-04-08

4.  A case of intrahepatic cholangiocarcinoma detected after successful interferon therapy for chronic hepatitis C.

Authors:  Hiroji Shinkawa; Seikan Hai; Hiromu Tanaka; Shigekazu Takemura; Kazuki Ohba; Takahiro Uenishi; Shintaro Kodai; Yorihisa Urata; Kazuhisa Kaneda; Masayuki Sakae; Kenichi Wakasa; Shoji Kubo
Journal:  Clin J Gastroenterol       Date:  2009-12-03

5.  Development of a hepatocellular carcinoma in a chronic hepatitis C patient 18 years after achieving a sustained virological response to interferon therapy: case report and literature review.

Authors:  Masaya Saito; Yasushi Seo; Yoshihiko Yano; Akira Miki; Yukiko Morinaga; Tomoo Itoh; Masaru Yoshida; Takeshi Azuma
Journal:  Clin J Gastroenterol       Date:  2012-02-18

6.  Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma.

Authors:  Hirokazu Miyatake; Yoshiyuki Kobayashi; Yoshiaki Iwasaki; Shin-Ichiro Nakamura; Hideki Ohnishi; Kenji Kuwaki; Junichi Toshimori; Hiroaki Hagihara; Kazuhiro Nouso; Kazuhide Yamamoto
Journal:  Dig Dis Sci       Date:  2011-10-12       Impact factor: 3.199

Review 7.  Adjuvant therapy after curative resection for hepatocellular carcinoma associated with hepatitis virus.

Authors:  Shoji Kubo; Shigekazu Takemura; Chikaharu Sakata; Yorihisa Urata; Takahiro Uenishi
Journal:  Liver Cancer       Date:  2013-01       Impact factor: 11.740

8.  Surgical treatment for hepatocellular carcinoma detected after successful interferon therapy.

Authors:  Shoji Kubo; Hiromu Tanaka; Shigekazu Takemura; Satoshi Yamamoto; Seikan Hai; Tsuyoshi Ichikawa; Shintaro Kodai; Hiroji Shinkawa; Taichi Shuto; Kazuhiro Hirohashi
Journal:  Surg Today       Date:  2007-03-26       Impact factor: 2.549

9.  Improvement of long-term outcomes in hepatitis C virus antibody-positive patients with hepatocellular carcinoma after hepatectomy in the modern era.

Authors:  Ken Shirabe; Kazuki Takeishi; Akinobu Taketomi; Hideaki Uchiyama; Hiroto Kayashima; Yoshihiko Maehara
Journal:  World J Surg       Date:  2011-05       Impact factor: 3.352

10.  Second hepatic resection for recurrent hepatocellular carcinoma in patients with chronic hepatitis C.

Authors:  Shoji Kubo; Shigekazu Takemura; Takahiro Uenishi; Takatsugu Yamamoto; Kazuki Ohba; Masao Ogawa; Seikan Hai; Tsuyoshi Ichikawa; Shintaro Kodai; Hiroji Shinkawa; Hiromu Tanaka
Journal:  World J Surg       Date:  2008-04       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.